ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Upadacitinib

First Posted Date: 2019-12-12

Last Posted Date: 2023-10-05

Lead Sponsor: AbbVie

Target Recruit Count: 485

Registration Number: NCT04195698

Locations: 🇺🇸
Dermatology Research Associates /ID# 218637, Los Angeles, California, United States
🇺🇸
University of Arkansas for Medical Sciences /ID# 221021, Little Rock, Arkansas, United States
🇺🇸
Clinical Science Institute /ID# 218632, Santa Monica, California, United States

and more 113 locations

A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation

Completed

Conditions: Hepatitis C Virus (HCV)

First Posted Date: 2019-12-06

Last Posted Date: 2022-06-27

Lead Sponsor: AbbVie

Target Recruit Count: 99

Registration Number: NCT04189627

Locations: 🇷🇺
Irkutsk Regional Center for the Prevention and Control of AIDS and Infections /ID# 222252, Irkutsk, Russian Federation
🇷🇺
Children's Clinical Multidisciplinary Center of the Moscow Region /ID# 226590, Moscow, Russian Federation
🇷🇺
Dagestan State Medical University /ID# 218500, Makhachkala, Dagestan, Respublika, Russian Federation

and more 5 locations

An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Cancer
Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Cofetuzumab Pelidotin

First Posted Date: 2019-12-06

Last Posted Date: 2024-06-18

Lead Sponsor: AbbVie

Target Recruit Count: 65

Registration Number: NCT04189614

Locations: 🇺🇸
The Ohio State University /ID# 211088, Columbus, Ohio, United States
🇺🇸
Stanford University School of Med /ID# 213450, Stanford, California, United States
🇪🇸
Hospital Universitario Fundacion Jimenez Diaz /ID# 215110, Madrid, Spain

and more 23 locations

A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma (MM)
Cancer

Interventions: Drug: ABBV-467

First Posted Date: 2019-11-26

Last Posted Date: 2021-07-26

Lead Sponsor: AbbVie

Target Recruit Count: 8

Registration Number: NCT04178902

Locations: 🇦🇺
Royal Adelaide Hospital /ID# 223354, Adelaide, South Australia, Australia
🇦🇺
Royal Perth Hospital /ID# 225498, Perth, Western Australia, Australia
🇦🇺
Perth Blood Institute Ltd /ID# 226650, Nedlands, Western Australia, Australia

and more 21 locations

A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical Practice

Recruiting

Conditions: Cancer, Chronic Lymphocytic Leukemia (CLL)

First Posted Date: 2019-11-26

Last Posted Date: 2024-06-18

Lead Sponsor: AbbVie

Target Recruit Count: 600

Registration Number: NCT04178317

Locations: 🇰🇷
Seoul National University Hospital /ID# 216853, Seoul, Korea, Republic of
🇰🇷
Kyungpook National University Hospital /ID# 233884, 중구, Daegu Gwang Yeogsi, Korea, Republic of
🇰🇷
Inje University - Busan Paik Hospital /ID# 233882, Busan, Busan Gwang Yeogsi, Korea, Republic of

and more 10 locations

A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

Phase 3

Active, not recruiting

Conditions: Spondyloarthritis

Interventions: Drug: Upadacitinib
Drug: Placebo

First Posted Date: 2019-11-19

Last Posted Date: 2024-06-18

Lead Sponsor: AbbVie

Target Recruit Count: 734

Registration Number: NCT04169373

Locations: 🇺🇸
Clinic of Robert Hozman/Clinical Investigation Specialists /ID# 215055, Skokie, Illinois, United States
🇺🇸
Arthritis & Rheumatic Disease Specialties /ID# 215306, Aventura, Florida, United States
🇨🇦
Toronto Western Hospital /ID# 215041, Toronto, Ontario, Canada

and more 209 locations

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

Phase 3

Active, not recruiting

Conditions: Irritable Bowel Syndrome With Constipation
Functional Constipation

Interventions: Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)
Drug: Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)

First Posted Date: 2019-11-18

Last Posted Date: 2024-06-20

Lead Sponsor: AbbVie

Target Recruit Count: 389

Registration Number: NCT04166058

Locations: 🇺🇸
River Birch Research Alliance /ID# 237963, Blue Ridge, Georgia, United States
🇺🇸
Advanced Research Center /ID# 237960, Anaheim, California, United States
🇺🇸
Dolphin Medical Research /ID# 234676, Doral, Florida, United States

and more 69 locations

A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)

Phase 3

Active, not recruiting

Conditions: Takayasu Arteritis (TAK)

Interventions: Drug: Upadacitinib
Drug: Placebo for Upadacitinib
Drug: Prednisolone

First Posted Date: 2019-11-13

Last Posted Date: 2024-10-04

Lead Sponsor: AbbVie

Target Recruit Count: 56

Registration Number: NCT04161898

Locations: 🇧🇷
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao /ID# 241175, Sao Paulo, Brazil
🇯🇵
Institute of Science Tokyo Hospital /ID# 214138, Bunkyo-ku, Tokyo, Japan
🇰🇷
The Catholic University of Korea, Seoul St. Marys Hospital /ID# 214566, Seoul, Seoul Teugbyeolsi, Korea, Republic of

and more 45 locations

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

Phase 3

Active, not recruiting

Conditions: Acute Myeloid Leukemia (AML)
Cancer

Interventions: Drug: Venetoclax
Drug: Azacitidine
Other: Best Supportive Care (BSC)

First Posted Date: 2019-11-13

Last Posted Date: 2025-01-03

Lead Sponsor: AbbVie

Target Recruit Count: 465

Registration Number: NCT04161885

Locations: 🇰🇷
The Catholic University of Korea, Seoul St. Marys Hospital /ID# 214892, Seoul, Seoul Teugbyeolsi, Korea, Republic of
🇪🇸
Hospital Clinic de Barcelona /ID# 215108, Barcelona, Spain
🇪🇸
Hospital Santa Creu i Sant Pau /ID# 240397, Barcelona, Spain

and more 162 locations

Expanded Access to Upadacitinib

Conditions: Atopic Dermatitis (AD)

First Posted Date: 2019-11-12

Last Posted Date: 2021-08-09

Lead Sponsor: AbbVie

Registration Number: NCT04159597

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy